Anthropic acquires biotech AI start-up for $400 million
What's the story
Anthropic, a leading player in the artificial intelligence (AI) space, has acquired Coefficient Bio, an AI biotech start-up. The deal is worth around $400 million and comes at a time when Anthropic is looking to expand its AI capabilities into domain-specific applications. The small but specialized team at Coefficient Bio will join Anthropic's healthcare division after the acquisition.
Tech integration
Coefficient Bio has developed AI platform for biotech workflows
Coefficient Bio has developed a platform that helps AI handle complex biotech workflows. These include drug discovery, research planning, and regulatory strategy development. The acquisition comes as part of Anthropic's broader strategy to expand its AI capabilities beyond general-purpose tools into domain-specific applications.
Strategic alliances
Anthropic has been enhancing Claude for scientific and medical use
In recent months, Anthropic has been working hard to improve its AI assistant Claude with features tailored for scientific and medical use cases. These include integrations with platforms like Benchling and BioRender, as well as tools for drafting clinical protocols and regulatory documents. The company has also announced collaborations with major pharmaceutical and research companies such as Sanofi, Novo Nordisk, Genmab and others.
Compliance update
Making AI compliant with medical data regulations
Earlier this year, Anthropic added features that allow healthcare professionals and insurers to use its AI systems in accordance with medical data regulations. This move is part of the company's ongoing efforts to make its technology compliant with industry standards. The acquisition of Coefficient Bio further strengthens these efforts by bringing in a specialized team and innovative platform into the fold.